908 Devices (NASDAQ:MASS – Get Free Report)‘s stock had its “sell (e+)” rating reaffirmed by investment analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.
Several other research firms also recently commented on MASS. Leerink Partners reiterated a “market perform” rating and issued a $4.00 price objective (down previously from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Stephens restated an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a research report on Wednesday. Stifel Nicolaus lowered their price objective on 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, Leerink Partnrs cut shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.33.
Read Our Latest Analysis on MASS
908 Devices Stock Performance
Hedge Funds Weigh In On 908 Devices
Several hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in 908 Devices in the third quarter worth about $36,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of 908 Devices during the 3rd quarter worth approximately $45,000. Drive Wealth Management LLC purchased a new position in shares of 908 Devices during the 3rd quarter worth approximately $50,000. Townsquare Capital LLC bought a new position in shares of 908 Devices in the 3rd quarter worth approximately $50,000. Finally, 49 Wealth Management LLC lifted its stake in shares of 908 Devices by 16.2% in the 3rd quarter. 49 Wealth Management LLC now owns 31,099 shares of the company’s stock valued at $108,000 after purchasing an additional 4,343 shares during the period. 88.06% of the stock is owned by hedge funds and other institutional investors.
About 908 Devices
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Recommended Stories
- Five stocks we like better than 908 Devices
- How to Read Stock Charts for Beginners
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- 3 REITs to Buy and Hold for the Long Term
- Oilfield Leader SLB: An AI Name You Need to Know
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.